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Abstract
We investigated the functional determinants of the cutaneous expression of elements of the hypothalamic^pituitary^
adrenal axis. In the present work, the presence of adrenocorticotropin (ACTH) peptide in skin of C57/BL6 mouse was
demonstrated by reversed-phase HPLC analysis combined with specific radioimmunoassay. ACTH concentration that was
low in telogen, increased during anagen in two steps: a rapid phase in anagen I, and a slower rise that reached its peak in
anagen VI. Immunofluorescence localized the ACTH antigen to the basal layer of epidermis, outer root sheath of hair follicle
and subcutaneous muscle of anagen VI skin. At physiological plasma concentration (1039 M), ACTH selectively stimulated
DNA synthesis in dermis, while pharmacological doses (1037^1036 M) inhibited DNA synthesis in both dermis and
epidermis. In conclusion, we suggest that local production of ACTH may represent a regulatory element in the control of
skin functions including hair growth. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Previous studies have documented that skin is a
target for POMC-derived peptides including adreno-
corticotropin (ACTH), melanocyte-stimulating hor-
mone (MSH) and L-endorphin, and expresses the
gene for proopiomelanocortin (POMC) [1^3]. Actual
POMC peptide production can be stimulated in
cultured skin cells with ultraviolet B (UVB) and se-
lected cytokines [1^6]. POMC gene transcription and
translation is hair cycle-dependent in the skin of
C57BL/6 mouse and increases signi¢cantly in the ac-
tive growth stage of the hair cycle (anagen) [7,8].
Local production of the POMC-derived peptide
L-endorphin exhibits signi¢cant hair cycle-dependent
changes as regards to the skin concentration and in
situ expression pattern, suggesting physiological in-
volvement in this process [7,9].
ACTH is a product of proteolytic processing and
modi¢cations of proopiomelanocortin [10^13]. A
30 kDa protein precursor is cleaved by convertase
PC1 producing the 16 kDa N-terminal peptide, a
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join peptide, ACTH and L-LPH. L-LPH is further
processed to L-endorphin and L-MSH. Another con-
vertase, PC2, cleaves the ¢rst 14 amino acids of the
ACTH sequence to generate ACTH(1^14)OH pep-
tide, precursor of K-MSH [11^13]. On the systemic
level ACTH induces adrenocortical production and
secretion of cortisol (humans) and corticosterone
(mice), steroids that attenuate POMC peptides pro-
duction [10,11]. However, depending on target tissue
and site of production, ACTH can also act as a
hormone, neurotransmitter, cytokine, biological
modi¢er and growth factor [10^13].
The speci¢c actions of ACTH in the skin include
stimulation of melanocyte melanogenesis and prolif-
eration [14] and sebocyte functional activity [6]. Clin-
ically, the administration of ACTH or its endoge-
nous overproduction can induce acne. ACTH may
also play a role in hair growth because intracutane-
ous administration of ACTH induces anagen devel-
opment in C57BL/6 mouse [15] and in mink [16]. To
further elucidate a potential role for ACTH in skin
physiology, we used the well-de¢ned C57BL/6 mouse
model for hair research [17,18]. We tested hair cycle-
dependent expression, cellular localization of ACTH
peptide and its phenotypic e¡ect.
2. Materials and methods
2.1. Animal model and tissue collection
C57BL/6 mice were purchased from Taconic (NY)
and housed in community cages at the animal facili-
ties of the Albany Medical College (Albany, NY) or
Virchow Hospital (Berlin, Germany). The animals
were fed with water and mouse chow ad libitum.
Active hair growth (anagen) was induced in the
back skin of 6- to 9-week-old C57BL/6 female mice
as previously described [7,17,18]. Hair cycle stages
were de¢ned according to the Chase classi¢cation:
telogen represents the resting phase, while anagen
corresponds to the growing phase of hair follicle
[18,19]. At least three mice were used for each time
point: telogen (untreated skin), anagen I (1 day post-
depilation (p.d.), anagen II (3 days p.d.), anagen IV
(5 days p.d.), anagen V (8 days p.d.) and anagen VI
(9^15 days p.d.). Mice were killed, and skin collected
and stored as described previously [7^9].
2.2. Reverse-phase high-pressure liquid
chromatography (RP-HPLC)
POMC peptides were extracted from anagen VI
skin as previously described using SEPCOL-1 con-
taining 200 mg of C18 according to the manufactur-
er’s protocol (cat. no. RIK-SEPCOL1, Peninsula,
CA) [9,20,21]. The samples were reconstituted in
0.1% tri£uoroacetic acid (TFA), separated by RP-
HPLC using a Beckman Ultrasphere C18 IP column
(4.6 mmU15.0 cm, 5 Wm pore size) [21]. Peptides
were eluted with a linear gradient of acetonitrile in
0.1% TFA (£ow rate =1 ml/min), and 1-ml fractions
were collected, lyophilized, and tested with radio-
immunoassay (RIA) kits for ACTH according to
the manufacturer’s protocol (cat. no. JRR3136, Ad-
vanced ChemTech, KY). The elution time for ACTH
was determined with synthetic peptide ACTH(1^39)
from Sigma (St. Louis, MO). Other peptide stand-
ards including desacetyl-K-MSH (ACTH(1^13)NH2),
K-MSH (K-N-acetylACTH(1^13)NH2), diacetyl-K-
MSH (K-N,O-diacetylACTH(1^13)NH2) and L-en-
dorphin were from Sigma.
2.3. Radioimmunoassay for ACTH
The RIA was performed using a commercial anti-
ACTH RIA kit (Incstar, Stillwater, MN) following
the manufacturer’s protocol. The antiserum did not
crossreact with POMC peptides, such as ACTH-
(1^10), ACTH(1^13) and K-MSH (crossreactivity
was less than 0.01%); it showed 100% reactivity
with ACTH(1^24) and ACTH(1^39) [4]. The results
are expressed as the mean from four assays þ S.D.
2.4. Immunohistochemistry
ACTH immunoreactivity (ACTH-IR) cryostat sec-
tions (8 Wm) of anagen VI skin ¢xed in acetone (10
min, 320‡C) and blocked with 10% normal goat
serum (15 min, room temperature) were incubated
with the primary rabbit antiserum against ACTH
at a ¢nal dilution: 1:200 (National Hormone and
Pituitary Program, National Institute of Diabetes,
Digestive and Kidney Diseases (NIDDKD)) [20]. In-
cubation was conducted overnight at room temper-
ature in a humid chamber. The following morning
TRITC-conjugated F(ab)2 fragments of goat anti-
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rabbit IgG in 2% normal goat serum (Jackson Im-
munoResearch, West Grove, PA) was added at a
dilution of 1:200 and further incubated for 30 min
at 37‡C. After every incubation, the sections were
washed as described previously [20]. The negative
control was represented by specimens incubated
without primary antibody. The sections were exam-
ined using a £uorescent Zeiss Axioscope microscope,
and photodocumented using a digital image analysis
system (ISIS METASYSTEM, Altlussheim, Ger-
many).
2.5. Skin organ culture
Four-mm punch biopsies of telogen skin were cul-
tured for 24 h at the air^liquid interface in Dulbec-
co’s modi¢ed Eagle’s medium containing 10% fetal
bovine serum and antibiotic/antimycotic mixture
(Gibco, NY), and 1 WCi/ml of [3H]thymidine (Tdr)
as described previously [22,23]. ACTH was added at
the concentrations listed in Fig. 4. At the end of
incubation the epidermis was separated from dermis
and the incorporation of Tdr into DNA was meas-
ured by liquid scintillation spectrometry [22,23]. The
results are presented as the mean þ S.E.M. per biopsy
punch (n = 14).
Statistical analyses were performed using inde-
pendent Student’s t-test.
3. Results and discussion
Fig. 1 shows the presence of ACTH peptide in
anagen VI skin. The major ACTH-IR peak most
likely represents authentic ACTH as it had the
same retention time (18^19 min) as the synthetic
ACTH standard. No speci¢c immunoreactivity was
detected at the retention time for the desacetyl-K-
MSH (13 min), K-MSH (15 min), diacetyl-K-MSH
(17 min), and L-endorphin (21 min).
ACTH concentration in telogen skin was detected
at 3.06 þ 3.59 pg/mg protein and increased signi¢-
cantly (P = 0.01) during anagen I following hair dep-
ilation (Fig. 2). Anagen II and IV skin showed a
slight not signi¢cant (Ps 0.05) decrease in ACTH
concentration in comparison to anagen I. The ana-
gen II and IV values were, however, higher than in
telogen (P6 0.015) (Fig. 2). In anagen V the ACTH
concentration was increased, being signi¢cantly high-
er than in anagen IV (P6 0.001) or anagen II (P =
0.002), and similar to anagen I (P = 0.093). ACTH
concentration reached a peak value of 107.6 þ 8.4 pg/
mg protein during anagen VI (Fig. 2). Indirect im-
muno£uorescence showed that ACTH-IR was
present in keratinocytes of basal layer of epidermis,
of proximal and distal outer root sheath (ORS) of
hair follicle, and in subcutaneous muscle (Fig. 3).
The rapid initial increase in cutaneous ACTH con-
Fig. 1. RP-HPLC identi¢cation of ACTH in anagen VI skin.
Elution time of desacetyl-K-MSH, K-MSH, diacetyl-K-MSH,
ACTH and L-endorphin standards was 13, 15, 17, 18^19 and
21 min, respectively.
Fig. 2. Changes in murine skin ACTH concentration during an-
agen development. The data represent mean þ S.D. (n = 4). Telo-
gen, anagen I, II, IV, V and VI correspond to days 0, 1, 3, 5, 8
and 12 after depilation (anagen induction), respectively [17,19].
BBAMCR 14393 11-11-98
A. Slominski et al. / Biochimica et Biophysica Acta 1448 (1998) 147^152 149
centration seen in this study coincides with the sim-
ilar increase noted in L-endorphin concentration [9].
Skin POMC mRNA concentration is very low during
anagen I, when only a 0.9 kb species is identi¢able
while POMC protein is undetectable [7,8]. Therefore,
the increases in ACTH and L-endorphin represent,
most likely, release of neuropeptides from local stor-
age sites or from nerve endings in reaction to depi-
lation trauma. However, the increased concentration
of ACTH during anagen V and VI may represent a
true increase in local production of the peptide, be-
cause it correlates with previous ¢ndings of full-
length 1.1 kb POMC mRNA in anagen IV, of 30
kDa POMC protein in anagen IV and V, and an
increased production of L-endorphin during anagen
VI [7^9].
The localization of ACTH-IR to keratinocytes of
basal layer of epidermis and ORS (Fig. 3A,B) is con-
sistent with the production of POMC peptides by
cultured keratinocytes [1^6]. It is also in agreement
with in situ detection of POMC mRNA in the epi-
dermis and ORS of hair follicle [24]. Likewise, the
presence of ACTH-IR in panniculus carnosus muscle
(Fig. 3B) is in agreement with the detection of
ACTH binding sites in muscular tissue and of
POMC-derived immunoreactivity in the neuromus-
cular system of the mice [25]. In conclusion, the ob-
served anagen V^VI associated increase of ACTH
concentration is most likely the result of its local
production.
In skin of C57BL6 mouse melanogenesis is
coupled to the anagen (growing) phase of hair cycle
[17]. Melanin synthesis starts in anagen III, increases
rapidly throughout anagen IV^VI and reaches a pla-
teau in anagen VI [26,27]. The current study shows
that ACTH also increases during anagen V to reach
a peak in anagen VI. This temporary correlation as
well as data documenting that ACTH acts as a stim-
ulator of melanin synthesis and melanocytic activity
[14] suggest a paracrine role for ACTH in the regu-
lation of melanogenesis. An alternative non-circadian
release of ACTH from the pituitary is unlikely, be-
cause it should be associated with corticosterone pro-
duction by the adrenal cortex generating, therefore,
the opposite e¡ect, e.g., abrupt termination of ana-
gen VI and attendant melanogenesis with induction
of premature catagen development (cf. Refs. [28^30]).
We applied previously established skin organ cul-
ture model to study the cutaneous e¡ect of ACTH in
an in vitro system in close to physiological conditions
[22,23]. The e¡ect of ACTH has been studied in non-
induced (telogen) skin. Fig. 4 shows a dose-depend-
ent and dual response to ACTH on DNA synthesis
in skin. At physiological doses (1039 M), ACTH
stimulates DNA synthesis in dermal (P6 0.01) but
not in epidermal (Ps 0.05) compartments, whereas
at pharmacological doses (1036^1037 M) it inhibits
DNA synthesis in both dermis and epidermis
(P6 0.01 and P6 0.001, respectively). Organ culture
studies previously documented that Tdr incorpora-
tion into epidermal and dermal compartments repre-
sents almost exclusively local DNA synthesis by epi-
dermal and follicular keratinocytes, respectively [23].
Thus, our own data on Tdr incorporation indicates
that ACTH can stimulate or inhibit DNA synthesis
in epidermal and follicular keratinocytes. In agree-
Fig. 3. Localization of ACTH-IR in back skin of adolescent C57Bl/6 mice during anagen VI. ACTH-IR in keratinocytes of the distal
part of ORS (A, arrow), in the basal layer of epidermis (A, arrowhead), in the proximal ORS (B, arrow), and in the subcutaneous
panniculus carnosus muscle (B, arrowhead). Negative control with omission of primary antiserum (C). EP, epidermis; ORS, outer
root sheath; PCM, panniculus carnosus muscle. Scale bars = 100 Wm.
BBAMCR 14393 11-11-98
A. Slominski et al. / Biochimica et Biophysica Acta 1448 (1998) 147^152150
ment with these ¢ndings, the intracutaneous injection
of ACTH is reported to induce anagen development
[15,16]. Moreover, MC2-R mRNA (receptor for
ACTH) has been detected in mouse and human
skin [28,31], and the related MC1-R is activated by
ACTH and expressed in mammalian keratinocytes
[32^35]. A dual e¡ect of ACTH on DNA synthesis
may be best interpreted as a result of direct activa-
tion of MC1 or MC2 receptors on keratinocytes or
as indirect e¡ect mediated by factors produced by
stimulation of the skin immune system.
In summary, we have identi¢ed for the ¢rst time
ACTH peptide in mouse skin, demonstrated signi¢-
cant hair cycle associated £uctuation in its concen-
tration, and localized ACTH-IR to keratinocytes of
epidermis, ORS and skeletal muscle. We are also
reporting that the peptide can regulate epidermal
and dermal DNA synthesis. Therefore, we propose
that local production of ACTH is a component of a
local regulatory system governing epidermal and hair
follicle activity.
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